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A b s t r a c t
Background: Familial hypercholesterolaemia (FH) is a monogenic lipid metabolism disorder characterised by markedly  
elevated serum low-density lipoprotein (LDL) cholesterol level due to a mutation in the LDL receptor gene. Clinical features 
of FH include premature atherosclerosis and coronary artery disease.
Aim: To explore associations between noninvasive markers of atherosclerosis including intima–media thickness (IMT) and 
pulse wave velocity (PWV) and blood lipids, blood pressure (BP) and obesity in a group of young patients with FH. 
Methods: Study population included 36 patients aged < 35 years with the diagnosis of FH based on the Simon Broome 
Register criteria, and their 49 relatives who comprised the control group free of FH. 
Results: Mean IMT values were higher in FH patients than controls (0.60 ± 0.19 vs. 0.53 ± 0.07 mm, respectively, p < 0.05). 
Mean body mass index (BMI) and waist circumference were similar in patients and controls. The prevalence of carotid ath-
erosclerotic plaques was significantly higher among FH patients (n = 6) than in controls (n = 1) (21.4% vs. 2.6%, p = 0.012). 
Arterial hypertension was present in 27.8% of patients with FH and 16.3% of subjects in the control group. Systolic blood 
pressure (SBP) in FH patients correlated significantly with age (r = 0.35), BMI (r = 0.48) and waist circumference (r = 0.47), 
and diastolic blood pressure (DBP) correlated with BMI (r = 0.42) and waist circumference (r = 0.41). PWV correlated sig-
nificantly with age (r = 0.44), SBP (r = 0.63) and DBP (r = 0.52). We did not find any correlations between IMT and serum 
lipids, BP or obesity indices in FH patients. 
Conclusions: Our findings show a higher rate of arterial hypertension in young FH patients compared to their relatives free 
of FH, with significant associations between BP and indices of obesity and arterial stiffness. Intensive lipid lowering and an-
tihypertensive therapy along with a reduction in central fat may be considered a mandatory treatment strategy in young FH 
patients to prevent atherosclerosis and increased arterial stiffness. 
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INTRODUCTION
Heterozygous familial hypercholesterolaemia (HeFH) oc-
curs at a rate of 1/500 in the general population and is 
one of the most common monogenic autosomal dominant 
disorders. Clinical and laboratory features of HeFH included 
elevated serum total cholesterol and low-density lipoprotein 
cholesterol (LDL-C) levels, tendinous xanthomas, arcus senilis 
of the cornea and xanthelasma palpebrarum [1, 2]. However, 
the most serious clinical manifestation is premature coronary 
atherosclerosis and ischaemic heart disease (IHD). About 50% 
of untreated men with HeFH develop IHD before 55 years 
of age, and women develop IHD on average 9 years later 
than men. Mortality among patients with HeFH is signifi-
cantly increased compared to healthy subjects of the same 
age and gender. Numerous studies showed that long-term 
lipid-lowering therapy with statins reduces coronary deaths 
and overall mortality in these patients [3–5]. Other major IHD 
risk factors in this population include arterial hypertension, low 
high-density lipoprotein cholesterol (HDL-C) level, diabetes 
and abdominal obesity.
In subjects without overt IHD, noninvasive evaluation 
of the severity and progression of atherosclerosis may be 
accomplished with measurements of carotid intima–media 
thickness (IMT) and arterial stiffness.
The aim of this study was to evaluate IHD risk factors 
(serum lipids, blood pressure, and obesity) and their relation 
to carotid IMT, a noninvasive marker of atherosclerosis, and 
pulse wave velocity (PWV), a marker of arterial stiffness, in 
young subjects with HeFH.
METHODS
Study group
Study population included 36 young patients (aged < 35 years) 
with the diagnosis of HeFH based on the Simon Broome Regi-
ster criteria, and their 49 age- and gender-matched relatives 
without HeFH. We included patients with both definitive and 
probable HeFH [6, 7]. The Simon Broome Register criteria for 
the diagnosis of HeFH are shown in Table 1. Exclusion criteria 
included severe liver or kidney disease and hypothyroidism. 
In all patients, clinical history was taken using a standardised 
questionnaire that included symptoms of IHD, other car-
diovascular disease, history of smoking, and treatment used. 
Hypertension was defined as blood pressure ≥ 140/90 mm Hg 
or the use of antihypertensive drugs. The study was approved 
by the Bioethics Committee at the Jagiellonian University 
Medical College.
Lipid levels
Blood for determination of lipid parameters was taken under 
fasting conditions. Serum lipid levels were measured by enzy-
matic methods using Roche kits. LDL-C level was estimated 
using the Friedewald formula. 
Carotid artery ultrasonography
The degree of vascular remodelling was evaluated by 
ultrasonographic IMT measurements in the common ca-
rotid artery. Measurements were performed manually in the 
two-dimensional long-axis view using a linear 10 MHz probe 
(GE VIVID 7 ultrasound machine). IMT was measured within 
near and far walls of both common carotid arteries, 2 cm 
proximally to the bifurcation into the internal and external 
carotid arteries (Fig. 1). All IMT measurements were per-
formed by two experienced and knowledgeable operators 
(previously trained and evaluated in research core laborato-
ries for the evaluation and analysis of IMT) who were blinded 
to the clinical characteristics of the study subjects. Three 
Table 1. Diagnostic criteria for familial hypercholesterolaemia 
(FH) according to the Simon Broome Register Group
Definite diagnosis of FH
a. Total cholesterol > 7.5 mmol/L (290 mg/dL) in adults
or total cholesterol > 6.7 mmol/L (260 mg/dL) in children  
below 16 years of age
OR
LDL cholesterol > 4.9 mmol/L (190 mg/dL) in adults 
(4.0 mmol/L in children)
PLUS
b. Tendon xanthomas in patient or in 1st or 2nd degree relative  
(parent, child, sibling, grandparent, uncle, aunt)
OR
c. Molecular diagnosis of FH based on the identification of  
apolipoprotein B or LDL receptor mutation
Probable diagnosis of FH: (a) PLUS (d) OR (e)
d. Family history of myocardial infarction below 50 years of age 
in a 2nd degree relative (grandparent, uncle, aunt) or below 
60 years of age in a 1st degree relative (parent, sibling, child)
e. Family history of elevated total cholesterol: > 7.5 mmol/L 
(290 mg/dL) in adult 1st or 2nd degree relative or > 6.7 mmol/L 
(260 mg/dL) in child or sibling aged below 16 years
Figure 1. Intima-media thickness (IMT) measurements in the 
common carotid artery
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measurements were performed at each arterial site. We 
evaluated both the mean of these three measurements and 
maximum IMT. Common carotid artery IMT > 0.9 mm was 
considered abnormal [8]. The number, size, and morpho logy 
of atherosclerotic plaques were described if such lesions 
were present. If an atherosclerotic plaque was present within 
the IMT evaluation area, measurements were limited to 
evaluation of the plaque and IMT measurement within the 
contralateral wall. Atherosclerotic plaques were defined as 
IMT > 1.5 mm or focal IMT increase by 0.5 mm or 50% of 
the IMT in the adjacent vascular segment [8]. Evaluation of 
intra-observer and inter-observer variability was performed 
in the early phase of study by calculating correlation coef-
ficients for the initial ten patients. In these calculations, 
intra-observer variability was 0.96 and 0.94, respectively, 
and inter-observer variability was 0.90. In our study group, 
no patients were excluded due to suboptimal quality of 
ultrasonographic images.
Evaluation of arterial stiffness
Arterial stiffness was evaluated by measurements of PWV 
between the carotid and femoral artery. The Complior device 
with a Fukuda sensor was used for these measurements.
Statistical analysis
Results obtained in the HeRH and control groups were com-
pared using the Mann-Whitney test. Associations between 
the studied variables were evaluated using the Pearson linear 
correlation coefficient. Finally, a multiple regression model 
was created by stepwise regression. P £ 0.05 was considered 
statistically significant. Statistical analyses were performed 
using the STATISTICA 10 package.
RESULTS
We studied 36 patients with a clinical diagnosis of HeFH and 
their 49 healthy relatives with normal serum lipid levels. Char-
acteristics of the studied subjects are shown in Table 2. As 
expected, mean LDL-C levels in patients with HeFH were 
significantly higher compared to healthy relatives. Mean IMT 
values were also higher in patients with HeFH compared to 
controls. Mean body mass index (BMI) and waist circumfer-
ence was similar in patients and relatives. Atherosclerotic 
plaques in the carotid arteries were observed significantly 
more frequently in patients with HeFH. In contrast, PWV 
values were similar in patients with HeFH and controls. Rates 
of hypertension were also similar in both groups. Smoking 
was reported by 15 subjects in the control group and only 
2 patients with HeFH. Only 30% of patients with HeFH were 
treated with statins. Table 3 shows correlation coefficients for 
Table 2. Study group characteristics
Parameter Patients with HeFH Control group P
Age [years] 27.3 ± 6.6 25.2 ± 6.7 NS
Body mass index [kg/m2] 23.6 ± 3.9 23.2 ± 4.5 NS
Waist circumference [cm] 80.4 ± 12.5 80.12 ± 12.7 NS
Waist-to-hip ratio 0.81 ± 0.09 0.82 ± 0.08 NS
SBP [mm Hg] 120.4 ± 16.2 121.4 ± 16.8 NS
DBP [mm Hg] 75.11 ± 11.06 77.9 ± 10.15 NS
Hypertension 10 (27.8%) 8 (16.3%) NS
HDL cholesterol [mmol/L] 1.49 ± 0.32 1.59 ± 0.82 NS
LDL cholesterol [mmol/L] 5.42±1.82 3.22±0.98 < 0.001
Pulse wave velocity [m/s] 8.4 ± 1.5 8.5 ± 1.1 NS
Intima–media thickness [mm] 0.60 ± 0.19 0.53 ± 0.07 0.047
Presence of carotid atherosclerotic plaques 6 (21.4%) 1 (2.6%) 0.012
Mean values ± SD are given unless stated otherwise; HeFH — heterozygous familial hypercholesterolaemia; SBP — systolic blood pressure;  
DBP — diastolic blood pressure; HDL — high-density lipoprotein; LDL — low-density lipoprotein
Table 3. Linear correlation coefficients between blood pressure 
and indices of obesity in patients with heterozygous familial 
hypercholesterolaemia
Parameter r p
Systolic blood pressure Age 0.35 0.04
BMI 0.48 0.003
WC 0.47 0.004
WHR 0.47 0.004
Diastolic blood pressure BMI 0.47 0.01
WC 0.41 0.01
WHR 0.37 0.03
BMI — body mass index; WC — waist circumference; WHR — waist-
-to-hip ratio
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relations between blood pressure and other evaluated vari-
ables. In patients with HeFH, systolic blood pressure (SBP) 
correlated significantly with age, BMI, waist circumference 
and waist-to-hip ratio, and diastolic blood pressure (DBP) 
correlated with BMI, waist circumference and waist-to-hip 
ratio. As expected, these correlations between blood pressure 
and indices of obesity were also significant in healthy controls.
The index of arterial stiffness, PWV, correlated signifi-
cantly with age, SBP, and DBP in patients with HeFH (Table 4). 
In the overall study population, PWV correlated with age, 
waist circumference, SBP, and DBP. A correlation between 
PWV and LDL-C level was observed only in healthy controls.
In the overall study population, we found that IMT, an 
established index of severity of vascular atherosclerotic lesions, 
significantly correlated with LDL-C level and age (Table 5). In 
contrast, patients with HeFH showed no correlations between 
IMT and lipid levels or age, and between lipid levels and blood 
pressure or obesity indices.
In the stepwise multiple regression model with IMT as the 
dependent variable and age, LDL-C, HDL-C, waist circumfer-
ence, SBP, and DBP as the independent variables showed that 
only age, LDL-C, and HDL-C were significant predictors of 
IMT, contributing to 31% of IMT variability. Age was the only 
significant predictor of IMT in subgroups of HeFH patients 
and controls, which might have been related to a small num-
ber of subjects in both these groups. In the regression model 
with PWV as the dependent variable, significant predictors 
included age and SBP in the overall study population, SBP in 
patients with HeFH, and age, waist circumference, and LDL-C 
level in healthy relatives (Table 6).
DISCUSSION
With the estimated rate of 1/500 in the general population, 
HeFH may be expected to affect about 70,000 persons in 
Poland but many such cases remain undetected, and many 
patients with established HeFH do not receive appropriate 
treatment. In our study group, the diagnosis of HeFH was 
based on the Simon Broome Register criteria which are used in 
everyday cardiology and general practice. The Polish Cardiac 
Society currently recommends, in accordance with the advice 
of an European Atherosclerosis Society and European Society 
of Cardiology expert panel, that the diagnosis of HeFH be 
made using clinical and biochemical criteria [9, 10].
In our study group, patients with a clinical suspicion of 
FH were characterised by increased IMT and a higher rate 
of carotid atherosclerotic plaques compared to age-matched 
young subjects with normal cholesterol level. In addition, 
Table 4. Linear correlation coefficients between pulse wave 
velocity (PWV), blood pressure, and lipid parameters in the 
overall study population, patients with heterozygous familial 
hypercholesterolaemia (HeFH), and subjects without HeFH
Parameter r p
PWV, overall Age 0.38 0.001
WC 0.30 0.01
SBP 0.43 0.000
DBP 0.41 0.001
PWV, HeFH Age 0.44 0.016
SBP 0.63 0.000
DBP 0.53 0.003
PWV, no HeFH LDL-C 0.41 0.011
Age 0.38 0.018
WC 0.42 0.008
WC — waist circumference; SBP — systolic blood pressure; DBP — dia-
stolic blood pressure; LDL-C — low-density lipoprotein cholesterol
Table 5. Linear correlation coefficients between mean intima-
-media thickness (IMT) and other evaluated parameters in the 
overall study population, patients with heterozygous familial 
hypercholesterolaemia (HeFH), and subjects without HeFH
Parameter r p
IMT, overall Age 0.37 0.002
LDL-C 0.27 0.03
WC 0.20 NS
IMT, no HeFH Age 0.512 0.001
WC 0.312 0.05
LDL-C 0.01 NS
IMT, HeFH Age 0.31 NS
LDL-C 0.132 NS
WC 0.175 NS
WC — waist circumference; LDL-C — low-density lipoprotein cholesterol
Table 6. Stepwise multiple regression models
b SE p
Dependent variable — mean IMT; independent variables: HDL-C, 
LDL-C, age, waist circumference, SBP, and DBP
Intercept 0.368 0.084 0.000
Age 0.010 0.002 0.000
LDL-C 0.016 0.007 0.035
HDL-C –0.075 0.036 0.040
Dependent variable — mean PVW; independent variables: 
HDL-C, LDL-C, age, waist circumference, SBP, and DBP
Intercept 3.663 1.103 0.001
SBP 0.028 0.008 0.001
Age 0.063 0.022 0.006
LDL-C –0.083 0.074 0.263
SE — standard error; IMT — intima–media thickness; HDL-C — high-
-density lipoprotein cholesterol; LDL-C — low-density lipoprotein chole-
sterol; SBP — systolic blood pressure; DBP — diastolic blood pressure; 
PWV — pulse wave velocity
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these young patients showed a higher rate of hypertension 
which was also related to obesity indices.
Carotid IMT is an established surrogate marker of 
the presence and severity of atherosclerotic plaques, and 
non-invasive carotid IMT measurements are frequently used 
to evaluate atherosclerotic lesions [11, 12]. They were also 
shown to correlate with other indices of atherosclerosis sever-
ity such as computed tomography-based calcium score [13]. 
Significantly higher IMT values and the presence of athero-
sclerotic plaques identified in the study subjects indicate an 
advanced atherosclerotic process in this population, as also 
reported by other authors [14, 15]. Carotid ultrasonography 
is prone to measurement errors (imprecise detection) and 
observations in small patient samples, such as in our study, 
may be chance findings but we attempted to minimise such 
biases by performing highly standardised measurements and 
evaluating intra- and inter-observer variability.
Significant correlations between IMT and age, BMI, 
waist circumference, SBP and DBP were reported by Ye et al. 
[16]. These authors also found correlations between carotid 
IMT and triglyceride, apolipoprotein B, and glucose levels, 
and the cholesterol-year score. A metaanalysis of 51 studies 
showed that total and LDL-C levels were significant predictors 
of femoral artery IMT in patients with HeFH, and of carotid 
artery IMT in subjects with familial combined hyperlipidaemia 
[17]. In this metaanalysis, reported by Masoura et al. [17], 
carotid IMT was found to be significantly higher in subjects 
with HeFH compared to the control group with normal lipid 
parameters. Overall, the mean IMT difference in all included 
studies was 0.12 mm (95% CI 0.09–0.15). Our observation 
of a higher prevalence of atherosclerotic plaques in patients 
with HeFH is also confirmed by the metaanalysis of Masoura 
et al. [17], although it should be noted that our analysis was 
limited to young subjects. Also similarly to our study, in the 
metaanalysis by Masoura et al. [17]. IMT was found to cor-
relate with subject age but not with serum lipid levels. The 
authors concluded that these findings suggested that the most 
important factor affecting IMT was the duration of exposure 
to the harmful effects of elevated cholesterol levels, and thus 
age was a stronger predictor of IMT than cholesterol level in 
these patients.
Ye et al. [16] also noted a significant correlation between 
the cholesterol-year score and IMT, but in those patients with 
a molecular diagnosis of HeFH, IMT showed a correlation 
with an inflammation marker, high sensitivity C-reactive 
protein level.
In the recent years, IMT has been frequently used as a sur-
rogate marker of atherosclerosis and a predictor of myocardial 
infarction and stroke. In a metaanalysis of 8 studies involving 
asymptomatic subjects, an increase of IMT by 0.1 mm was 
found to be associated with an increase in the adjusted risk 
of myocardial infarction by 10%, and of stroke by 14% [18]. 
Taking into account the fact that only 30% of our patients 
with HeFH were treated with statins, our findings confirm 
the need for more aggressive identification of young subjects 
with HeFH and earlier initiation of treatment in these patients.
In a study of 12 patients with HeFH, Bellanger et al. 
[19] showed a reverse association between cholesterol efflux 
mediated by HDL2-dependent scavenger receptor-B1 and 
ABCG1 and IMT. These results suggest a major role of HDL in 
the pathogenesis of vascular lesions in patients with HeFH. In 
our regression analysis, HDL-C level correlated negatively with 
IMT, which is consistent with findings by Bellanger et al. [19].
Results of our study showed a high rate of hypertension 
among patients with HeFH. We also found a significant as-
sociation between PWV and blood pressure, although similar 
PWV was noted in patients and controls. In a group of children 
with familial and polygenic hypercholesterolaemia, whose 
average age was 10 years, Italian authors found higher PWV 
compared to the control group, while IMT values were similar 
in those children with hypercholesterolaemia and controls 
[20]. In addition, cholesterol level showed an association with 
PWV in that population but children with elevated blood 
pressure were excluded from the study.
In a study of 436 subjects with LDL receptor defects, 
higher blood pressure values were observed compared to the 
control group [11]. In our patients with HeFH, blood pressure 
showed expected correlations with age and indices of obesity 
including waist circumference and waist-to-hip ratio. These 
findings suggest that in addition to lipid-lowering therapy, 
antihypertensive drug therapy along with strategies to reduce 
abdominal fat (diet and physical activity) have an important 
role in prevention of atherosclerosis and increased arterial stiff-
ness in this patient population. Emerging data of importance 
for prevention of hypertension indicate that infections may 
also be related to elevated blood pressure in these patients 
[21]. Studies on molecular defects underlying HeFH are also 
important for prevention of IHD. Junyent et al. [11] reported 
a significant association between carotid IMT and the type of 
LDL receptor mutation, which highlights the role of the genetic 
evaluation of HeFH beyond providing a secure diagnosis, 
although not all authors confirmed such a relationship [22].
Despite the fact that smoking was reported by 2 patients 
with HeFH and 15 subjects in the control group, IMT values 
were found to be significantly higher in patients compared to 
controls, which also emphasizes the risk associated with lipid 
abnormalities and hypertension.
CONCLUSIONS
Young patients with a clinical suspicion of familial hypercho-
lesterolaemia were characterised by expectedly higher LDL-C 
levels, along with higher IMT values and a higher rate of carotid 
atherosclerotic plaques compared to age-matched young sub-
jects with normal cholesterol level. Prevalence of hypertension 
was also higher in patients with HeFH compared to the control 
group, and blood pressure values correlated with indices of 
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obesity including waist circumference, BMI, and waist-to-hip 
ratio. Our findings suggest that in addition to lipid-lowering 
therapy, antihypertensive drug therapy along with strategies 
to reduce abdominal fat (diet and physical activity) have an 
important role in prevention of atherosclerosis and increased 
arterial stiffness in this patient population.
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S t r e s z c z e n i e 
Wstęp: Rodzinna heterozygotyczna hipercholesterolemia (RHH) jest monogenowym zaburzeniem metabolizmu lipidów cechującym 
się znacznym podwyższeniem stężenia cholesterolu LDL w wyniku mutacji w genie receptora LDL. RHH występuje z częstością ok. 
1/500 osób w populacji. W Polsce RHH dotyczy ok. 70 000 chorych, jednak znaczna ich część pozostaje niezdiagnozowana, a oso-
by z ustalonym rozpoznaniem często nie są leczone lub leczone nieadekwatnie. Charakterystyczne cechy kliniczne RHH obejmują 
podwyższenie stężenia cholesterolu całkowitego i cholesterolu LDL w surowicy, zmiany skórne o typie żółtaków ścięgien prostow-
ników palców, ścięgna Achillesa, rąbek starczy oraz żółtaki powiek. Najgroźniejszym objawem klinicznym RHH jest przedwczesna 
miażdżyca naczyń wieńcowych i choroba niedokrwienna serca. Umieralność nieleczonych pacjentów z RHH jest znacznie większa 
niż osób zdrowych tej samej płci i wieku. 
Cel: W niniejszym badaniu oceniono związek między grubością błony intima–media (IMT) i prędkością fali tętna, nieinwazyjnymi 
markerami miażdżycy naczyń a stężeniem lipidów, ciśnieniem tętniczym krwi i otyłością w grupie młodych pacjentów z RHH. 
Metody: Badaniem objęto 36 młodych pacjentów z rozpoznaniem RHH na podstawie  kryteriów Simon Broome Register, w wie-
ku < 35 lat i ich 49 krewnych bez RHH, stanowiących grupę kontrolną, dobraną pod względem wieku i płci. U wszystkich chorych 
przeprowadzono wywiad wg standardowego kwestionariusza, obejmujący dane na temat obecności choroby niedokrwiennej serca, 
chorób układu sercowo-naczyniowego, nałogu palenia tytoniu oraz sposobu leczenia.
Wyniki: Średnie wartości IMT były wyższe u osób z RHH niż w grupie kontrolnej: 0,60 ± 0,19 vs. 0,53 ± 0,07 mm (p < 0,05). 
Średnie wartości wskaźnika masy ciała (BMI) i obwód pasa były podobne w obu grupach. Pacjenci z RHH cechowali się częstszym 
występowaniem blaszek miażdżycowych (n = 6) niż grupa kontrola (n = 1) (21,4% vs. 2,6%; p = 0,012). Nadciśnienie tętnicze 
występowało u 27,8% pacjentów z RHH i u 16,3% osób z grupy kontrolnej. Ciśnienie skurczowe u osób z RHH korelowało istotnie 
z wiekiem (r = 0,35), BMI (r = 0,48) i obwodem pasa (r = 0,47), a ciśnienie rozkurczowe z BMI (r = 0,42) i obwodem pasa (r = 0,41). 
Prędkość fali tętna korelowała istotnie z wiekiem (r = 0,44), ciśnieniem skurczowym (r = 0,63) i rozkurczowym (r = 0,52). Nie zaob-
serwowano korelacji między IMT a stężeniem lipidów surowicy, ciśnieniem tętniczym lub wskaźnikami otyłości u pacjentów z RHH. 
Wnioski: Wyniki wskazują, że odsetek osób z nadciśnieniem tętniczym jest wyższy u młodych pacjentów z RHH niż u krewnych 
bez RHH oraz na obecność silnej korelacji między ciśnieniem tętniczym a wskaźnikami otyłości (takimi jak obwód pasa, BMI, współ-
czynnik pas/biodra) oraz sztywnością naczyń. Intensywne leczenie hipolipemizujące i hipotensyjne, a także zmniejszenie otyłości 
brzusznej wydają się ważnymi elementami leczenia młodych pacjentów z RHH w celu prewencji miażdżycy i sztywnienia naczyń. 
Słowa kluczowe: rodzinna hipercholesterolemia, miażdżyca, szyjna IMT
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